Supplementary Tables – Real-world treatment patterns and overall survival in BRAF-mutant melanoma patients treated with immunotherapy or targeted therapy

   Sensitivity analysis 1: Statistical adjustment without inverse probability of treatment weighting (IPTW)    Sensitivity analysis 2: Censoring patients in the practice subanalysis who initiate a therapy off-sequence    Sensitivity analysis 3: Restricting to CPI patients receiving ipilimumab + nivolumab    Supplemental Table 1. Comparison of statistical adjustments with and without inverse probability of treatment weighting (IPTW).    Supplemental Table 2. Baseline Characteristics of Patients With Advanced BRAF-Mt Melanoma by 1L Treatment</p

Supplementary Figures – Real-world treatment patterns and overallsurvival in BRAF-mutant melanoma patientstreated with immunotherapy or targetedtherapy

   Supplemental Figure 1. Kaplan-Meier Estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT.    Supplemental Figure 2. Kaplan-Meier estimates of Overall Survival (OS) in Patients With Advanced BRAF-Mt Melanoma Receiving 1L Treatment With CPI (ipilimumab/nivolumab) or TT weighted by IPTW.</p